Elekta financing investments in R&D with long-term loans

12/17/2002 6:00 AM EST

Stockholm 17 December 2002

Elekta intends to increase its investments in research and development. New, advanced systems and clinical solutions for stereotactic and intensity modulated (IMRT) radiotherapy are currently under development. These systems are intended to improve precision treatment of cancer of the lungs, liver and prostate. Moreover, further development is under way of Elekta's world-leading system for stereotactic radiosurgery, Leksell Gamma Knife®, for effective treatment of brain disorders.

With the aim of securing financing for these long-term R&D programs, Elekta has assumed a long-term loan with the Nordic Investment Bank. The loan amounts to USD 27 million, with a maturity of seven years.


Elekta is a world-leading supplier of advanced and innovative radiation oncology and neurosurgery solutions and services for precise treatment of cancer and brain disorders. Elekta's solutions are clinically effective, cost efficient and gentle to the patient.

For further information, please contact:

Håkan Bergström CFO, Elekta AB (publ)
Tel: +46 8 587 255 47